Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024. "BOT/BAL represents one of the most significant advancements in cancer immunotherapy, showing remarkable results in MSS colorectal cancer where previous treatments have fallen short," said Garo Armen, Ph.D., Chairman and CEO of Agenus. "Its potential extends beyond this challenging cancer type, with promising efficacy seen in the neoadjuvant setting and other hard-to-treat cancers. While we are excited by

Novel Candidates Show Promise in Turning Cold and Refractory Tumors into Responsive Targets Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational immunotherapy candidates, botensilimab and AGEN1721, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas. The data, showcasing potential breakthroughs in treating immune-resistant tumors, will be presented by Dhan Chand, Ph.D., Vice President of Research at Agenus. The first two presentations will spotlight botensilimab, an innovative, investigational, Fc-enhanced ant

Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter

Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 12th, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/932317413. About A

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate administration Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety profiles These data advance the science of co-administration of recommended adult vaccines GSK plc (NYSE:GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) when co-administered with SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted), both AS01-adjuvanted vaccines (NCT059660

BOT/BAL Demonstrates Broad and Durable Activity in Advanced Sarcoma Population Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, presented data today at the European Society for Medical Oncology (ESMO) Congress held in Barcelona, Spain. The data from a Phase 1 study of botensilimab (BOT), an investigational Fc-enhanced CTLA-4 inhibitor, in combination with balstilimab (BAL), an investigational PD-1 antibody, showed clinical activity in patients with refractory sarcomas, a population with limited treatment options. "The continued activity with additional patients and longer follow-up of BOT/BAL in this study reinforces it's po

Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Agenus executives, Dr. Garo Armen, Chief Executive Officer, Robin Taylor, Chief Commercial Officer, and Zack Armen, Head of Investor Relations, will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference: Fireside chat will be held in-person on Thursday, September 5th at 12:45 p.m. ET in Boston, MA. A live webcast and replay will be accessible at https://cc.webcasts.com/well001/090424a_js/?entity=119_VLEQW2Q and on the Events and Presentations page of Agenus' website. HC Wainwright Global Investmen

Robust Phase 2 Data Validate Consistent Clinical Activity of BOT/BAL in Metastatic MSS CRC Maturing Data Across BOT/BAL Program Demonstrate Broad Solid Tumor Activity in the Late Stage, First-Line with Chemo Combinations, and Neoadjuvant disease Commenced Interactions with Global Regulatory Authorities for BOT/BAL Approval Pathways Data from ESMO GI Demonstrate Pathologic Complete Responses with BOT/BAL Therapy in Neoadjuvant CRC Patients Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the second quarter of 2024. "Agenus milest

Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, bran

Agenus Inc. (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the publication of a seminal study in the prestigious Cancer Discovery, a journal of the American Association for Cancer Research, detailing the novel mechanism of action and effectiveness of botensilimab, an investigational, novel multifunctional anti-CTLA-4 antibody, in various treatment-resistant cancers. The paper, entitled "Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective Against Tumors Poorly Responsive to Conventional Immunotherapy," highlights several key findings: Demonstrated Activity Across Multiple Cancers: Botensilimab has shown increased ac

10-Q - AGENUS INC (0001098972) (Filer)

8-K - AGENUS INC (0001098972) (Filer)

8-K/A - AGENUS INC (0001098972) (Filer)

8-K - AGENUS INC (0001098972) (Filer)

8-K - AGENUS INC (0001098972) (Filer)

424B5 - AGENUS INC (0001098972) (Filer)

10-Q - AGENUS INC (0001098972) (Filer)

8-K - AGENUS INC (0001098972) (Filer)

S-8 - AGENUS INC (0001098972) (Filer)

8-K - AGENUS INC (0001098972) (Filer)

4 - AGENUS INC (0001098972) (Issuer)

4 - AGENUS INC (0001098972) (Issuer)

4 - AGENUS INC (0001098972) (Issuer)

4 - AGENUS INC (0001098972) (Issuer)

4 - AGENUS INC (0001098972) (Issuer)

4 - AGENUS INC (0001098972) (Issuer)

4 - AGENUS INC (0001098972) (Issuer)

4 - AGENUS INC (0001098972) (Issuer)

4 - AGENUS INC (0001098972) (Issuer)

4 - AGENUS INC (0001098972) (Issuer)

4 - AGENUS INC (0001098972) (Issuer)

4 - AGENUS INC (0001098972) (Issuer)

Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, bran

Strategic leadership to drive next phase of growth for the company Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.

Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie Fagan Appointed Chief Communications Officer Immuno-oncology leader, Agenus Inc. ("Agenus") (NASDAQ:AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company's next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics. Chief Commercial Officer, Robin Ta

BETHESDA, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C. Evan Ballantyne as the Company's Chief Financial Officer, effective immediately. Mr. Ballantyne succeeds Salvatore Calabrese, who is expected to remain employed by the Company for a reasonable transition period to enable an orderly transition of duties. "I am thrilled to be joining the Gain team at this exciting time in the Company's development," said Mr. Ballantyne, Chief Financial Officer. "Gain's lead program with disease-modifyi

Patricia Carlos named Chief Regulatory, Quality, and Safety OfficerTodd Yancey, MD named Senior Global Clinical Development, Medical Affairs and Commercial Advisor LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the appointment of Patricia Carlos as Chief Regulatory, Quality, and Safety Officer; Todd Yancey, MD as Global Clinical Development, Medical Affairs and Commercial Development Advisor. "Our upcoming worldwide Phase 2 botensilimab "ACTIVATE" programs in MSS colorectal cancer and metastatic melanoma are

Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has elected Manuel Hidalgo Medina, M.D., Ph.D., to the Board, effective June 1, 2021. Dr. Hidalgo will serve as a member of the Science & Technology Committee of the Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005285/en/Chief of the Division of Hematology and Medical Oncology, Weill Cornell Medicine and New York-Presbyterian/Weill Cornell Medical Center (Photo: Business Wire) "We are delighted to welcome Manny to our Board of Directors," said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the appointment of Andy Hurley as its Chief Commercial Officer. “We welcome Andy Hurley as we transition into a commercial stage company with a robust research and clinical pipeline,” said Garo Armen, PhD, Chairman and CEO of Agenus. “Andy’s experience and passion in successfully commercializing biopharmaceutical agents and his excitement about our portfolio made him a natural fit to join our team.” "I am excited

Jefferies analyst Biren Amin downgrades Agenus (NASDAQ:AGEN) from Buy to Hold and raises the price target from $3 to $7.

Thursday, Agenus Inc. (NASDAQ:AGEN) announced the results of its end-of-Phase 2 meeting with the FDA to advance its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for adult patients with relapsed/refractory microsatellite-stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM). The FDA discouraged the accelerated approval pathway and advised against submitting these results to support an Accelerated Approval based on its view that objective response rates may not translate to survival benefits. Given the limited treatment options for late-stage colorectal cancer and the promising survival data from the Phase I trial of botensilimab plus balsti

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Thursday. The Dow traded down 1.08% to 40,752.05 while the NASDAQ fell 0.80% to 17,853.34. The S&P 500 also fell, dropping, 0.75% to 5,546.48. Check This Out: Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July Leading and Lagging SectorsEnergy shares jumped by 1.1% on Thursday. In trading on Thursday, health care shares fell by 1.6%. Top Headline Abbott Laboratories (NYSE:ABT) reported better-than-expected earnings for its second quarter on Thursday. The company posted sales of $10.38 billion, up 4%, almost in line with the consensus of $10.37 bil

Shares of Domino’s Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results. The company reported second-quarter FY24 sales growth of 7.1% year-on-year to $1.097 billion, missing the analyst consensus estimate of $1.103 billion. The company is temporarily suspending its guidance metric of 1,100+ global net stores growth until the full effect of DPE's store opens and closures on international net store growth are known. Domino’s Pizza shares dipped 11.2% to $420.36 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Onconetix, Inc. (NASDAQ:ONCO) climbed 97.6% to $0.2944. On July 15, Oncon

HC Wainwright & Co. analyst Emily Bodnar downgrades Agenus (NASDAQ:AGEN) from Buy to Neutral and lowers the price target from $40 to $9.

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 200 points on Thursday. The Dow traded down 0.61% to 40,947.68 while the NASDAQ fell 1.22% to 17,776.55. The S&P 500 also fell, dropping, 0.79% to 5,544.08. Check This Out: Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July Leading and Lagging SectorsEnergy shares jumped by 0.7% on Thursday. In trading on Thursday, information technology shares fell by 0.8%. Top Headline U.S. initial jobless claims increased by 10,000 to 243,000 in the week ending July 13, compared to market estimates of 230,000. Equities Trading UP                        CommScope Holding Com

Agenus Inc. (NASDAQ:AGEN) stock is trading lower on Thursday, with a session volume of 6.29 million, according to data from Benzinga Pro. The company announced the results of its end-of-Phase 2 (EOP2) meeting with the FDA to advance its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for adult patients with relapsed/refractory microsatellite-stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM). The FDA discouraged the accelerated approval pathway and advised against submitting these results to support an Accelerated Approval based on its view that objective response rates may not translate to survival benefits. Agenus previously disclosed

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 40 points on Thursday. Following the market opening Thursday, the Dow traded up 0.10% to 41,238.64 while the NASDAQ rose 0.22% to 18,036.66. The S&P 500 also rose, gaining, 0.21% to 5,600.18. Check This Out: Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July Leading and Lagging SectorsIndustrials shares jumped by 0.6% on Thursday. In trading on Thursday, health care shares fell by 0.4%. Top Headline D.R. Horton, Inc. (NYSE:DHI) reported better-than-expected second-quarter earnings on Thursday. D.R. reported quarterly earnings of $4.10 per share which beat the analyst consensus

NKGN: 88% | NKGen Biotech Will Present New Biomarker Data On SNK01 In Alzheimer's Disease During A Poster Presentation At The Upcoming Alzheimer's Association International Conference From July 28 – August 1 AGEN: -63% | Agenus shares are trading lower after the company announced the FDA discouraged an accelerated approval pathway at the end-of-Phase 2 meeting. BYND: -25% | Beyond Meat shares are trading lower following a report suggesting the company's liquidity has weakened and it is engaging bondholders for debt discussions.

Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024. "BOT/BAL represents one of the most significant advancements in cancer immunotherapy, showing remarkable results in MSS colorectal cancer where previous treatments have fallen short," said Garo Armen, Ph.D., Chairman and CEO of Agenus. "Its potential extends beyond this challenging cancer type, with promising efficacy seen in the neoadjuvant setting and other hard-to-treat cancers. While we are excited by

Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter

Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 12th, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/932317413. About A

Robust Phase 2 Data Validate Consistent Clinical Activity of BOT/BAL in Metastatic MSS CRC Maturing Data Across BOT/BAL Program Demonstrate Broad Solid Tumor Activity in the Late Stage, First-Line with Chemo Combinations, and Neoadjuvant disease Commenced Interactions with Global Regulatory Authorities for BOT/BAL Approval Pathways Data from ESMO GI Demonstrate Pathologic Complete Responses with BOT/BAL Therapy in Neoadjuvant CRC Patients Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the second quarter of 2024. "Agenus milest

Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations. About Agenus Agenus is a leading immuno-oncology compan

$100M royalty financing agreement with Ligand announced, bringing in capital via non-equity means to support critical botensilimab/balstilimab (BOT/BAL) development and launch readiness activities Company has reestablished its market compliance with Nasdaq Listing Notable clinical results observed in Phase 1 and Phase 2 studies of BOT/BAL in metastatic relapsed/refractory colorectal cancer setting (r/r MSS CRC NLM) Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the first quarter 2024. In a concurrent press release accompanying Agenus' earnings announcement, a $100M royalty f

Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/928123199. About Agen

FDA Grants Fast Track designation for BOT/BAL in metastatic, refractory colorectal cancer (CRC) patients who have failed 1st and 2nd line standard of care treatments Data from Phase 1 of BOT/BAL in refractory CRC showed durable ORR of 24% in patients with non-active liver metastases (NLM); Completed enrollment of randomized Phase 2 trial (n=230) Clinical data sets path for expansion opportunities in pancreas, lung, neoadjuvant CRC, and melanoma Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023. "In

Conference Call on Thursday, March 14, 2024 at 8:30 a.m. ET Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Company will release its fourth quarter and year end 2023 financial results before the market opens on Thursday, March 14, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenu